NYSE - Delayed Quote ? USD
AbbVie Inc. (ABBV)
At close: September 11 at 4:00 PM EDT
After hours: September 11 at 7:57 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
55,000,000.00
54,318,000.00
58,054,000.00
56,197,000.00
45,804,000.00
--
Cost of Revenue
20,485,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
--
Gross Profit
34,515,000.00
33,903,000.00
40,640,000.00
38,751,000.00
30,417,000.00
--
Operating Expense
20,794,000.00
20,368,000.00
21,826,000.00
19,703,000.00
17,678,000.00
--
Operating Income
13,721,000.00
13,535,000.00
18,814,000.00
19,048,000.00
12,739,000.00
--
Net Non Operating Interest Income Expense
-1,735,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
--
Other Income Expense
-4,920,000.00
-5,601,000.00
-3,293,000.00
-3,675,000.00
-7,061,000.00
--
Pretax Income
7,066,000.00
6,250,000.00
13,477,000.00
12,989,000.00
3,398,000.00
--
Tax Provision
1,716,000.00
1,377,000.00
1,632,000.00
1,440,000.00
-1,224,000.00
--
Net Income Common Stockholders
5,298,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
--
Diluted NI Available to Com Stockholders
5,298,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
--
Basic EPS
3.00
2.75
6.69
6.53
2.62
--
Diluted EPS
2.99
2.72
6.63
6.45
2.62
--
Basic Average Shares
1,768,500.00
1,765,940.73
1,769,181.29
1,768,337.70
1,765,132.82
--
Diluted Average Shares
1,772,500.00
1,773,000.00
1,778,000.00
1,777,000.00
1,765,132.82
--
Total Operating Income as Reported
12,272,000.00
12,757,000.00
18,117,000.00
17,924,000.00
11,363,000.00
--
Total Expenses
41,279,000.00
40,783,000.00
39,240,000.00
37,149,000.00
33,065,000.00
--
Net Income from Continuing & Discontinued Operation
5,339,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
--
Normalized Income
6,495,920.46
5,583,720.00
12,578,755.00
12,586,575.00
5,672,310.00
--
Interest Income
770,000.00
540,000.00
186,000.00
39,000.00
174,000.00
--
Interest Expense
2,505,000.00
2,224,000.00
2,230,000.00
2,423,000.00
2,454,000.00
--
Net Interest Income
-1,735,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
--
EBIT
9,571,000.00
8,474,000.00
15,707,000.00
15,412,000.00
5,852,000.00
--
EBITDA
18,087,000.00
17,172,000.00
24,174,000.00
23,933,000.00
12,323,000.00
--
Reconciled Cost of Revenue
20,485,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
--
Reconciled Depreciation
8,516,000.00
8,698,000.00
8,467,000.00
8,521,000.00
6,471,000.00
--
Net Income from Continuing Operation Net Minority Interest
5,339,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
--
Total Unusual Items Excluding Goodwill
-1,528,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
--
Total Unusual Items
-1,528,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
--
Normalized EBITDA
19,615,000.00
18,096,000.00
25,019,000.00
25,108,000.00
13,770,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-371,079.54
-203,280.00
-102,245.00
-130,425.00
-390,690.00
--
12/31/2019 - 1/2/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRK Merck & Co., Inc.
114.71
-0.54%
JNJ Johnson & Johnson
164.82
-1.53%
PFE Pfizer Inc.
29.66
-0.27%
BMY Bristol-Myers Squibb Company
48.59
-1.40%
LLY Eli Lilly and Company
920.89
+2.18%
AMGN Amgen Inc.
329.98
+0.32%
GILD Gilead Sciences, Inc.
80.94
-0.61%
AZN AstraZeneca PLC
80.53
-0.78%
GSK GSK plc
43.77
-0.75%
NVS Novartis AG
115.28
-1.46%